| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
20,281 |
19,078 |
$3.24M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
7,475 |
6,886 |
$1.47M |
| S9083 |
Global fee urgent care centers |
7,502 |
7,010 |
$855K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
21,533 |
16,590 |
$690K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
18,249 |
17,479 |
$389K |
| 99215 |
Prolong outpt/office vis |
1,725 |
1,660 |
$225K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
12,855 |
12,424 |
$199K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,160 |
1,098 |
$190K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,314 |
1,262 |
$172K |
| 71046 |
Radiologic examination, chest; 2 views |
1,630 |
1,577 |
$110K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
903 |
875 |
$100K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,255 |
1,189 |
$95K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,703 |
1,645 |
$87K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,282 |
1,186 |
$87K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
364 |
343 |
$73K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
283 |
274 |
$42K |
| 73610 |
|
256 |
247 |
$39K |
| 99205 |
Prolong outpt/office vis |
221 |
219 |
$34K |
| 81001 |
|
1,888 |
1,817 |
$17K |
| 94664 |
|
1,181 |
1,086 |
$17K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
675 |
599 |
$13K |
| 73630 |
|
160 |
152 |
$13K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
434 |
413 |
$12K |
| 84703 |
|
269 |
260 |
$8K |
| 73140 |
|
164 |
155 |
$8K |
| 87807 |
|
236 |
226 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
13 |
12 |
$4K |
| 73110 |
|
27 |
27 |
$3K |
| 74019 |
|
40 |
37 |
$3K |
| 73564 |
|
44 |
43 |
$3K |
| 12011 |
|
14 |
12 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
294 |
284 |
$3K |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
25 |
25 |
$3K |
| 87581 |
|
466 |
452 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,000 |
966 |
$712.18 |
| 87077 |
|
81 |
79 |
$612.55 |
| 29515 |
|
67 |
64 |
$300.00 |
| 29130 |
|
14 |
12 |
$225.00 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
24 |
24 |
$182.55 |
| 87486 |
|
416 |
404 |
$172.57 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
939 |
914 |
$167.93 |
| 87186 |
|
31 |
30 |
$0.00 |
| 85007 |
|
13 |
13 |
$0.00 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
123 |
121 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
189 |
179 |
$0.00 |
| 85027 |
|
13 |
13 |
$0.00 |